IFNG and neoplasm: Multiple mechanisms, such as downregulation of the immune checkpoint ligands by the tumor, activation of alternative cancer signaling pathways, mutations in genes involved in IFN-γ signaling, immuno-editing and changes in the tumor microenvironment (TME) have been shown to contribute to both primary and acquired resistance to immune checkpoint inhibitors [5,6].